1. TSLP acts on regulatory T cells to maintain their identity and limit allergic inflammation.
- Author
-
Gurram RK, Li P, Oh J, Chen X, Spolski R, Yao X, Lin JX, Roy S, Liao MJ, Liu C, Yu ZX, Levine SJ, Zhu J, and Leonard WJ
- Subjects
- Animals, Mice, Th2 Cells immunology, Hypersensitivity immunology, Inflammation immunology, Mice, Inbred C57BL, Mice, Knockout, Receptors, Cytokine immunology, Receptors, Cytokine genetics, Mice, Transgenic, Immunoglobulins, T-Lymphocytes, Regulatory immunology, Cytokines immunology, Cytokines metabolism, Thymic Stromal Lymphopoietin
- Abstract
Thymic stromal lymphopoietin (TSLP) is a type I cytokine that promotes allergic responses and mediates type 2 immunity. A balance between effector T cells (T
effs ), which drive the immune response, and regulatory T cells (Tregs ), which suppress the response, is required for proper immune homeostasis. Here, we report that TSLP differentially acts on Teffs versus Tregs to balance type 2 immunity. As expected, deletion of TSLP receptor (TSLPR) on all T cells ( Cd4Cre Crlf2fl/fl mice) resulted in lower numbers of T helper 2 (TH 2) cells and diminished ovalbumin-induced airway inflammation, but selective deletion of TSLPR on Tregs ( Foxp3YFP -Cre/Y Crlf2fl/fl mice) resulted in increased interleukin-5 (IL-5)- and IL-13-secreting TH 2 cells and lung eosinophilia. Moreover, TSLP augmented the expression of factors that stabilize Tregs . During type 2 immune responses, TSLPR-deficient Tregs acquired TH 2-like properties, with augmented GATA3 expression and secretion of IL-13. TSLP not only is a driver of TH 2 effector cells but also acts in a negative feedback loop, thus promoting the ability of Tregs to limit allergic inflammation.- Published
- 2025
- Full Text
- View/download PDF